Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Valomaciclovir: Phase IIb started

November 12, 2007 8:00 AM UTC

Epiphany began a Phase IIb trial to compare once-daily valomaciclovir vs. thrice-daily Valtrex valacyclovir from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). Medivir granted Epiphany worldwide ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article